Jazz Pharmaceuticals (JAZZ) EBITDA (2010 - 2026)

Jazz Pharmaceuticals' EBITDA history runs 17 years deep, the most recent figure standing at $336.6 million for Q1 2026.

• In Q1 2026, EBITDA rose 384.21% year-over-year to $336.6 million; the TTM figure through Mar 2026 stood at -$37.7 million (down 105.24% YoY), while the FY2025 annual figure was -$430.2 million, down 160.04% from the prior year.
• EBITDA was $336.6 million for Q1 2026 at Jazz Pharmaceuticals, up from $254.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $336.6 million in Q1 2026 to a low of -$686.4 million in Q2 2025.
• Historically, EBITDA has averaged $67.1 million across 5 years, with a median of $122.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA plunged 633.39% in 2022, then jumped 596.17% in 2023.
• A 5-year view of EBITDA shows it stood at -$263.4 million in 2022, then surged by 146.51% to $122.5 million in 2023, then soared by 55.73% to $190.8 million in 2024, then jumped by 33.43% to $254.5 million in 2025, then surged by 32.24% to $336.6 million in 2026.
• The last three EBITDA figures came in at $336.6 million (Q1 2026), $254.5 million (Q4 2025), and $57.5 million (Q3 2025), per Business Quant data.